Helix Unveils Landmark Genomic Screening Findings at ASHG 2026 Plenary Session
Helix, renowned for its advancements in precision medicine, is set to share significant findings from a three-year study on population genomic screening during the opening plenary session of the 2026 Annual Meeting of the American Society of Human Genetics (ASHG). This prestigious event will take place from October 20 to 24 in Montreal, Canada.
Drawing from data gathered through the Helix Research Network®, which constitutes the largest precision health network in existence, this presentation will highlight the achievements of 17 prominent health systems that are now incorporating genomics as a part of standard care across various medical services. The study emphasizes how revealing previously undiagnosed genetic risks can lead to improved screening and preventive strategies within diverse healthcare environments.
The Helix Research Network's innovative initiatives cover a plethora of medical areas, including liver disease, dementia, heart disease, and kidney disease. Attendees can look forward to a series of platform presentations and posters that demonstrate how this network of health systems cultivates a learning approach, allowing for the identification of new insights, their application in clinical settings, and the assessment of their real-world effects.
William Lee, Ph.D., the Chief Science and Product Officer at Helix, expressed enthusiasm about the conference, stating, "The Helix Research Network combines large-scale genomic research with a practical application aimed at improving clinical outcomes. We are excited to showcase how Helix is facilitating the integration of novel clinical approaches with tangible outcomes measurements in real time."
The plenary session will feature key clinical findings and presentations, including:
The late-breaking poster session will introduce findings on how CYP2C19 pharmacogenomic testing and subsequent interventions have successfully reversed problematic hospitalization trends for patients on clopidogrel, highlighting the direct clinical impacts of genomic knowledge.
For those attending ASHG 2026, Helix invites participants to engage with the team at booth #1200, offering an opportunity to explore the innovative applications of genomics in healthcare. This presentation stands as a testament to Helix's ongoing commitment to enhancing the health of populations through actionable genomic insights and effective preventive care strategies. As the landscape of healthcare becomes increasingly intertwined with genomic discoveries, Helix remains at the forefront, guiding clinical practices toward more informed, personalized care.
To discover more about Helix and their contributions to the field of genomics, please visit their official website at www.helix.com.
Drawing from data gathered through the Helix Research Network®, which constitutes the largest precision health network in existence, this presentation will highlight the achievements of 17 prominent health systems that are now incorporating genomics as a part of standard care across various medical services. The study emphasizes how revealing previously undiagnosed genetic risks can lead to improved screening and preventive strategies within diverse healthcare environments.
The Helix Research Network's innovative initiatives cover a plethora of medical areas, including liver disease, dementia, heart disease, and kidney disease. Attendees can look forward to a series of platform presentations and posters that demonstrate how this network of health systems cultivates a learning approach, allowing for the identification of new insights, their application in clinical settings, and the assessment of their real-world effects.
William Lee, Ph.D., the Chief Science and Product Officer at Helix, expressed enthusiasm about the conference, stating, "The Helix Research Network combines large-scale genomic research with a practical application aimed at improving clinical outcomes. We are excited to showcase how Helix is facilitating the integration of novel clinical approaches with tangible outcomes measurements in real time."
The plenary session will feature key clinical findings and presentations, including:
- - Plenary Session: A three-year outcomes study on CDCT1 Screening involving 527,000 participants. Scheduled for Tuesday, October 20, from 5:57 PM to 6:15 PM ET in Room 517/Level 5.
- - Presentation on Kidney Function: Research quantifying the distinct genetic variations linked to kidney function decline, utilizing multi-state Markov analysis from over 3.4 million eGFR measurements across 13 health systems, to be presented on Wednesday, October 21, from 11:45 AM to 12:00 PM ET.
- - GLP1R Variants Study: A session to discuss rare GLP1R variants and their selective effects on weight loss with semaglutide, versus the impact of tirzepatide, scheduled for Thursday, October 22, from 1:45 PM to 2:00 PM ET.
- - Posters on Clinical Findings: Multiple posters will also be shared throughout the event, addressing various topics, such as the influence of the APOE genotype on the progression from mild cognitive impairment to dementia and the implications of genetic variance regarding liver disease cases.
The late-breaking poster session will introduce findings on how CYP2C19 pharmacogenomic testing and subsequent interventions have successfully reversed problematic hospitalization trends for patients on clopidogrel, highlighting the direct clinical impacts of genomic knowledge.
For those attending ASHG 2026, Helix invites participants to engage with the team at booth #1200, offering an opportunity to explore the innovative applications of genomics in healthcare. This presentation stands as a testament to Helix's ongoing commitment to enhancing the health of populations through actionable genomic insights and effective preventive care strategies. As the landscape of healthcare becomes increasingly intertwined with genomic discoveries, Helix remains at the forefront, guiding clinical practices toward more informed, personalized care.
To discover more about Helix and their contributions to the field of genomics, please visit their official website at www.helix.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.